Appointed
Junyi Dai
Chairman
Indaptus Therapeutics, Inc.
On March 18, 2026, the Board of Directors appointed Junyi Dai as Chairman of the Board of Directors, effective March 18, 2026.
other_material
confidence high
sentiment neutral
materiality 0.85
Indaptus Therapeutics change of control: David Lazar sells $11.2M stake; new CEO Junyi Dai appointed
Indaptus Therapeutics, Inc.
- David Lazar sold 700K Series AAA and 196.8K Series AA Preferred shares to five purchasers for $11.2M.
- Purchasers will own 96.2% of diluted shares post-conversion; may be deemed a group under Exchange Act.
- Four directors resigned, including co-CEO Jeffrey Meckler; David Lazar resigned as co-CEO but remains on board.
- Junyi Dai, 39, appointed CEO and Chairman; previously Managing Director at FLMD Pty Ltd and independent director.
- Company to file resale registration statement within 30 days for 2.064M shares underlying Lazar's retained Series AA.
item 5.01item 1.01item 5.02item 9.01
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Role change
David Lazar
Chairman
Indaptus Therapeutics, Inc.
David Lazar resigned as co-Chief Executive Officer on March 18, 2026, but remains on the Board of Directors, while stepping down as Chairman.
Departed
Jeffrey A. Meckler
Director
Indaptus Therapeutics, Inc.
Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes (together, the “Resigning Directors”) resigned on March 18, 2026.
Departed
William B. Hayes
Director
Indaptus Therapeutics, Inc.
Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes (together, the “Resigning Directors”) resigned on March 18, 2026.
Appointed
Junyi Dai
Chief Executive Officer
Indaptus Therapeutics, Inc.
Furthermore, on March 18, 2026, the Board appointed Junyi Dai as the Chief Executive Officer of the Company, effective at Closing of the March 2026 SPA.
Departed
Anthony J. Maddaluna
Director
Indaptus Therapeutics, Inc.
Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes (together, the “Resigning Directors”) resigned on March 18, 2026.
Departed
Jeffrey A. Meckler
co-Chief Executive Officer
Indaptus Therapeutics, Inc.
Mr. Meckler also resigned as co-Chief Executive Officer on March 18, 2026.
Departed
Roger J. Pomerantz
Director
Indaptus Therapeutics, Inc.
Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes (together, the “Resigning Directors”) resigned on March 18, 2026.
Role change
David Lazar
co-Chief Executive Officer
Indaptus Therapeutics, Inc.
David Lazar resigned as co-Chief Executive Officer on March 18, 2026, but remains on the Board of Directors, while stepping down as Chairman.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.